GlassScriptPhysician profile
Alice Cheung
NPI 1639638778
$3,853.43
in general payments reported to CMS, 2019-2025
24 companies · $1,340 in 2025
The $1,340 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,513 · 2025: $1,340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,143 · Travel and Lodging: $1,675 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,143.20 |
| Travel and Lodging | $1,675.17 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,112.95 | 2024-2025 | Tactra, Ams 800 Artificial Urinary Sphincter |
| Axonics, INC. | $305.63 | 2024 | Axonics, Bulkamid |
| Sumitomo Pharma America, INC. | $231.14 | 2025 | Gemtesa, Orgovyx |
| Procept Biorobotics Corporation | $175.82 | 2025 | |
| Janssen Biotech, INC. | $164.21 | 2024-2025 | Erleada |
| Antares Pharma, INC. | $154.95 | 2024-2025 | Xyosted |
| Urogen Pharma, INC. | $126.39 | 2025 | |
| Calyxo, INC. | $72.24 | 2025 | Cvac Aspiration System |
| Coloplast Corp | $69.62 | 2024-2025 | |
| Pfizer INC. | $46.18 | 2025 | |
| Abbvie INC. | $44.47 | 2025 | |
| Myriad Genetic Laboratories, INC. | $42.88 | 2025 | Myrisk |
| Ethicon US, LLC | $40.75 | 2024 | Surgicel Nu-Knit, Stratafix |
| Endo USA, INC. | $37.06 | 2025 | Aveed, Xiaflex |
| Medtronic, INC. | $36.70 | 2025 | Interstim |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Bayer Healthcare Pharmaceuticals INC. | $28.83 | 2025 | |
| Ferring Pharmaceuticals INC. | $23.30 | 2025 | Adstiladrin |
| Teleflex LLC | $21.83 | 2025 | Barrigel |
| Progenics Pharmaceuticals, INC. | $20.48 | 2025 | |
| Merck Sharp & Dohme LLC | $18.32 | 2025 | Keytruda |
| Dendreon Pharmaceuticals LLC | $17.51 | 2025 | Provenge |
| Telix Pharmaceuticals | $13.64 | 2025 | Illuccix |
| Astellas Pharma US INC | $13.47 | 2025 | Xtandi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alice Cheung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.